Improving the care of people with multiple sclerosis through implementing NICE guidancePeople with multiple sclerosis (MS) need services that are specialized and responsive to their needs. They require thorough and sensitive assessment of problems and need to be able to access services when required. ...
The National Institute for Health and Care Excellence (NICE) issued guidance this week on the diagnosis, treatment, and aftercare of adult patients with chronic heart failure. One multiple sclerosis (MS) charity called NICE's decision not to recommend ocrelizumab for people with primary progressive ...
NICE’s final draft guidance from the drug cost-effectiveness body confirms a first draft decision published in January. In its decision NICE alluded to the host of rival therapies, both oral and injected, that are already on the market, such as Roche’s Ocrevus (ocrelizumab) and Biogen’s...
Reports that the process used by Great Britain's National Institute for Clinical Excellence (NICE) to evaluate drugs in England and Wales has been hit with criticism over its decision on interferon beta as a treatment for multiple sclerosis. Accusations of being uncooperative, uncommunicative and bi...
NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance.
NICE [National Institute for Clinical Excellence] announces members of UK's [United Kingdom] first Citizens Council Anderson 被引量: 0发表: 2002年 Guide to the methods of technology appraisal The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to the...
The UK’s National Institute for Health and Care Excellence (NICE) has given a green light to reimbursement of Sanofi’s Lemtrada therapy for multiple sclerosis (MS) on the NHS. Final guidance published this week concludes that Lemtrada (alemtuzumab) is cost-effective for adults with active, ...
It will help more people with multiple sclerosis to live a normal life.” A spokesperson for Biogen commented: “The NICE guidance is good news for people in England and Wales who are starting treatment for RRMS. This is important as approximately 100,000 people in the UK have MS. “For ...
An evaluation of the impact of NICE guidance on GP prescribing. BACKGROUND: One of the aims of the National Institute for Clinical Excellence (NICE) is to promote faster access to the best treatments. However, there is ... B Wathen,T Dean - 《British Journal of General Practice the Journa...
1 Independent Researcher, 1096 HZ Amsterdam, The Netherlands 2 Independent Researcher, 30159 Hannover, Germany * Author to whom correspondence should be addressed. Downloadkeyboard_arrow_down Versions Notes Abstract The British National Institute for Health and Care Excellence (NICE) recently published its...